Reported about 14 hours ago
The U.S. Supreme Court has rejected former pharmaceutical CEO Martin Shkreli's appeal regarding a $64.6 million financial penalty linked to his price hike of the lifesaving drug Daraprim. Shkreli raised the drug's price by over 4,000% in 2015, leading to a civil antitrust case from the government. While the ruling upheld the significant penalty, Shkreli's appeal did not contest the lifetime ban from the pharmaceutical industry imposed by Judge Denise Cote. Shkreli's attorney indicated that there may be future opportunities to challenge the ruling based on new legal precedents.
Source: YAHOO